Caris Life Sciences Inc (CAI)

$18.15 +0.46 (2.60%)
Market Cap 5.13B
Revenue (ttm) 812.03M
Net Income (ttm) -68.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 121.00
Profit Margin -8.39%
Debt to Equity Ratio 0.66
Volume 1,697,500
Avg Vol 2,439,752
Day's Range N/A - N/A
Shares Out 282.58M
Stochastic %K 23%
Beta N/A
Analysts Strong Sell
Price Target $32.80

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions;...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 771 8946
Fax: 866 479 4925
Address:
750 West John Carpenter Freeway, Suite 800, Irving, United States
appayip
appayip Mar. 13 at 3:12 PM
$CAI what are your long term price targets?
1 · Reply
appayip
appayip Mar. 12 at 2:41 PM
$CAI buy order filled. can't wait to hear more results of their early detection test. this company is great in the long run too actually, if i am not mistaken, they makes agreement with big pharma, when they find a medicine by using data of Caris, they will give caris percentage from their revenue of that medicine.
0 · Reply
microeone
microeone Mar. 10 at 5:04 PM
$CAI the blinded validation study results are likely to be released by the end of this month for Caris detect… how is everyone feeling on the probability of the sensitivity and specificity to remain intact? Management sounded very optimistic and bullish on the last earnings call. Big moment because Cari’s detect commercial launch was not factored into 2026 revenue.
0 · Reply
prismmarketview
prismmarketview Mar. 9 at 4:32 PM
Caris Life Sciences (NASDAQ: $CAI) has launched a proprietary Caris AI Insights signature for pancreatic ductal adenocarcinoma that plugs into its Molecular Tumor Board Report, using whole‑exome and whole‑transcriptome sequencing plus clinical data from a 550,000‑patient real‑world database to steer first‑line regimen choice between FOLFIRINOX and gemcitabine/nab‑paclitaxel and flag patients who may safely de‑escalate therapy. https://prismmarketview.com/caris-life-sciences-launches-ai-driven-tool-to-guide-pancreatic-cancer-treatment/
0 · Reply
DARKP00L
DARKP00L Mar. 9 at 1:05 PM
$CAI 08:39 on Mar. 09 2026 Caris Life Sciences Launches AI-Driven Pancreatic Cancer Signature To Guide First-Line Treatment In Pancreatic Ductal Adenocarcinoma #tradeideas
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 7 at 1:38 AM
$CAI Current Stock Price: $18.58 Contracts to trade: $17.5 CAI Mar 20 2026 Call Entry: $0.80 Exit: $1.01 ROI: 26% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
derektorM
derektorM Mar. 5 at 5:28 PM
$CAI thin liquidity name quietly basing watching for sudden volume expansion
0 · Reply
VrilDozer14
VrilDozer14 Mar. 4 at 2:55 AM
$CAI I work for this company. I’m really not sure what’s up w the price. It’s a good company I’ve worked there for 15 years. It’s gotta be over sold.
1 · Reply
appayip
appayip Mar. 2 at 10:12 AM
$CAI $TEM $TALK it is not secret, anyone who is interested in AI know it already. It was the reason i invested in Caris.
1 · Reply
Jasooon
Jasooon Mar. 1 at 8:03 PM
$CAI $TEM $TALK This guy is right, data is as, if not more, important than the AI tech itself. CAI, TEM, and Talkspace have huge moat from all the data that have collected and will continue to collect in their areas.
0 · Reply
Latest News on CAI
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

May 23, 2025, 5:54 PM EDT - 10 months ago

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

Caris Life Sciences discloses rise in revenue in US IPO filing

May 23, 2025, 5:12 PM EDT - 10 months ago

Caris Life Sciences discloses rise in revenue in US IPO filing

Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO

May 23, 2025, 4:22 PM EDT - 10 months ago

Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO

Caris Life Sciences IPO Registration Document (S-1)

May 23, 2025, 3:27 PM EDT - 10 months ago

Caris Life Sciences IPO Registration Document (S-1)

appayip
appayip Mar. 13 at 3:12 PM
$CAI what are your long term price targets?
1 · Reply
appayip
appayip Mar. 12 at 2:41 PM
$CAI buy order filled. can't wait to hear more results of their early detection test. this company is great in the long run too actually, if i am not mistaken, they makes agreement with big pharma, when they find a medicine by using data of Caris, they will give caris percentage from their revenue of that medicine.
0 · Reply
microeone
microeone Mar. 10 at 5:04 PM
$CAI the blinded validation study results are likely to be released by the end of this month for Caris detect… how is everyone feeling on the probability of the sensitivity and specificity to remain intact? Management sounded very optimistic and bullish on the last earnings call. Big moment because Cari’s detect commercial launch was not factored into 2026 revenue.
0 · Reply
prismmarketview
prismmarketview Mar. 9 at 4:32 PM
Caris Life Sciences (NASDAQ: $CAI) has launched a proprietary Caris AI Insights signature for pancreatic ductal adenocarcinoma that plugs into its Molecular Tumor Board Report, using whole‑exome and whole‑transcriptome sequencing plus clinical data from a 550,000‑patient real‑world database to steer first‑line regimen choice between FOLFIRINOX and gemcitabine/nab‑paclitaxel and flag patients who may safely de‑escalate therapy. https://prismmarketview.com/caris-life-sciences-launches-ai-driven-tool-to-guide-pancreatic-cancer-treatment/
0 · Reply
DARKP00L
DARKP00L Mar. 9 at 1:05 PM
$CAI 08:39 on Mar. 09 2026 Caris Life Sciences Launches AI-Driven Pancreatic Cancer Signature To Guide First-Line Treatment In Pancreatic Ductal Adenocarcinoma #tradeideas
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 7 at 1:38 AM
$CAI Current Stock Price: $18.58 Contracts to trade: $17.5 CAI Mar 20 2026 Call Entry: $0.80 Exit: $1.01 ROI: 26% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
derektorM
derektorM Mar. 5 at 5:28 PM
$CAI thin liquidity name quietly basing watching for sudden volume expansion
0 · Reply
VrilDozer14
VrilDozer14 Mar. 4 at 2:55 AM
$CAI I work for this company. I’m really not sure what’s up w the price. It’s a good company I’ve worked there for 15 years. It’s gotta be over sold.
1 · Reply
appayip
appayip Mar. 2 at 10:12 AM
$CAI $TEM $TALK it is not secret, anyone who is interested in AI know it already. It was the reason i invested in Caris.
1 · Reply
Jasooon
Jasooon Mar. 1 at 8:03 PM
$CAI $TEM $TALK This guy is right, data is as, if not more, important than the AI tech itself. CAI, TEM, and Talkspace have huge moat from all the data that have collected and will continue to collect in their areas.
0 · Reply
Jasooon
Jasooon Feb. 28 at 1:50 PM
$CAI yahhh
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 28 at 2:28 AM
$CAI Share Price: $20.12 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $2.89 – $3.57 Target Zone: $4.79 – $5.86 Potential Upside: 57% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Feb. 27 at 1:58 PM
Baird maintains Caris Life Sciences $CAI at Outperform and raises the price target from $26 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
briefingcom
briefingcom Feb. 27 at 1:25 PM
$CAI: Caris Life Sciences (+14.3%) completes interim readout of Achieve 1 Study; Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260226180139CAI&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
GambleLifeAway
GambleLifeAway Feb. 27 at 1:10 PM
After such a positive earnings call with several upcoming catalysts mentioned from $CAI , Piglosi needs to dump all her useless $TEM stock for a real Precision Medicine company - $CAI . After all, $TEM is in the selling data to pharma business, not helping cancer patients.
0 · Reply
Ron12341
Ron12341 Feb. 27 at 10:46 AM
$CAI JPM price cuts price target to $35 from $40. Still representing 80% upside from yesterday’s close.
0 · Reply
char13
char13 Feb. 27 at 10:46 AM
$CAI 19% premkt
0 · Reply
Jasooon
Jasooon Feb. 27 at 3:31 AM
$CAI they've hit their operating leverage. Most of the growth will go straight to the bottom line. This has become a FCF compounding stock machine. Q4 GMs were over 75%. They have moat.
0 · Reply
Jasooon
Jasooon Feb. 27 at 3:29 AM
$CAI they say cash is king. The FCF turnaround is amazing. Great financial profile, trading at low multiple, and founder-led. Big balance sheet and Takeda contract to execute on. The future is bright.
0 · Reply
topstockalerts
topstockalerts Feb. 26 at 11:24 PM
After Hours Top Gainers PT2 $DLLL $NFXL $AAOI $CAI $PRAA
0 · Reply
StockNews_Live
StockNews_Live Feb. 26 at 11:00 PM
$CAI Caris Life Sciences announced an interim readout of Achieve 1, a study supporting the upcoming launch of Caris Detect, its multi-cancer early detection test. The study demonstrated the superiority of …
0 · Reply
microeone
microeone Feb. 26 at 9:57 PM
$CAI only would the sick people on Wall Street try to drive down a profitable biotech company hoping to improve cancer detection and treatments… hope they never need the products. Great report
0 · Reply